Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Mr Logic who wrote (725)	2/13/1998 7:09:00 AM
From: Mark Bartlett	Read Replies (1) \| Respond to of 14101

Patrick, <<The way I would like to see Dimethaid go is similar to, say, Macrochem. OK, it may be able to do a lot, but let's focus on doing two or three things well, and getting them to market.>> I agree completely. The company needs to get one drug to market and get some recognition/credibility and cash flow. Once that happens, IMO they will get the attention they need from the street. I think 1998 is going to be the start of that process ... many of us have been patient for a couple of years - time for the seeds they planted to start bearing a little fruit. I model DMX around Biochem ..... their one drug (TC3) catapulted them to the moon. IMO DMX has more potential than Biochem - much more. But it is going to take time for the events to unfold. Take care, MB